Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared an article on X:
“The DESTINY-Breast04 study highlights a critical issue—persistent, subtle nausea and fatigue that patients experience compared to standard chemotherapy.
Read the papers for details. That’s why patients have shared concerns about the impact of Enhertu (T-DXd) on quality of life.”
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC.
Authors: Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Yeon Hee Park, Hope S Rugo, Binghe Xu, Fatima Cardoso, Zahi Mitri, Reshma Mahtani, Cecilia Orbegoso Aguilar, Feng Xiao, Nadia Harbeck, David A Cameron, Shanu Modi.
You can read the Full Article on Journal of The Oncologist.
More posts featuring Naoto T Ueno.